



I claim:

1. A compound having the formula




wherein R_2 is hydrogen, a monomeric glycoside or an oligomeric glycoside, R_3 is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula $-\text{CH}(\text{CH}_3)\text{C}(=\text{O})\text{OCH}_2\text{O}-R_8$, R is a lower alkylene, R' is

selected from the group consisting of moieties having the formula




where $X = 0$ or 1 , $Y = 0$ or 1 , R_1 is hydrogen or a pharmacologically active drug residue, R_8 a pharmacologically active drug residue, R_4 , R_5 , and R_6 are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




and R_7 is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

- 5 2. The compound of Claim 1 wherein R_7 is hydroxyl.
3. The compound of Claim 2 having the formula




- wherein R_2 and R_3 are independently hydrogen, a monomeric glycoside or an oligomeric glycoside, R' is selected from the group consisting of




- 20 where $X = 0$ or 1 , $Y = 0$, R_1 is hydrogen or a pharmacologically active drug residue, and R_4 , R_5 , and R_6 are independently hydrogen, alkyl, aryl, aralkyl, or cycloalkyl.

4. The compound of Claim 3 having the formula



5. The compound of Claim 4 having the formula


5



15

6. The compound of Claim 5 having the formula


20



30

35 7. The compound of Claim 6 wherein R₂ has the formula


40



50


where n = 0 to about 8.

8. The compound of Claim 7 having the formula



20 where $n = 0$ to about 8.


9. The compound of Claim 4 having the formula



10. The compound of Claim 9 having the formula




11. The compound of Claim 9 having the formula




12. The compound of Claim 11 having the formula




13. The compound of Claim 12 having the formula




14. The compound of Claim 11 having the formula




15. The compound of Claim 14 having the formula




16. The compound of Claim 4 having the formula




17. The compound of Claim 16 having the formula




18. The compound of Claim 17 wherein R_3 has the formula




5 19. The compound of Claim 18 having the formula



20. The compound of Claim 18 having the formula




21. The compound of Claim 17 having the formula



22. The compound of Claim 21 having the formula


5

15



23. The compound of Claim 16 having the formula


30



24. The compound of Claim 23 having the formula


40

50



25. The compound of Claim 23 having the formula


10



20

26. The compound of Claim 23 having the formula


30



40

27. The compound of Claim 23 having the formula


50



60


28. The compound of Claim 6 having the formula

10



29. The compound of Claim 6 having the formula


25




35

40 30. The compound of Claim 16 having the formula

50




31. A pharmaceutical composition useful for the treatment of inflammatory bowel disease or for reducing inflammation which composition comprises an inflammation reducing effective amount of a compound having the formula




wherein R_2 is hydrogen, a monomeric glycoside or an oligomeric glycoside, R_3 is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula $\text{—CH}(\text{CH}_3)\text{C}(=\text{O})\text{OCH}_2\text{O—R}_8$, R is a lower alkylene, R' is

selected from the group consisting of moieties having the formula



where $X = 0$ or 1 , $Y = 0$ or 1 ,


R_1 is hydrogen or a pharmacologically active drug residue, R_8 a pharmacologically active drug residue, R_4 , R_5 , and R_6 are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




and R₇ is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

5 32. The composition of Claim 1 wherein R₇ is hydroxyl.

33. The composition of Claim 32 comprising a compound having the formula




and its pharmaceutically acceptable salt, wherein R₂ and R₃ are independently hydrogen, a monomeric glycoside or an oligomeric glycoside, R' is selected from the group consisting of



where X = 0 or 1, Y = 0,

R₁ is hydrogen or a pharmacologically active drug residue, and R₄, R₅, and R₆ are independently hydrogen, alkyl, aryl, aralkyl, or cycloalkyl.


25 34. The composition of Claim 33 comprising a compound having the formula



and its pharmaceutically acceptable salt.

35. The composition of Claim 34 comprising a compound having the formula


10



20 and its pharmaceutically acceptable salt.

36. The composition of Claim 35 comprising a compound having the formula

30




and its pharmaceutically acceptable salt.

37. The composition of Claim 36 wherein R_2 has the formula


45

55




where n = 0 to about 8.

38. The composition of Claim 37 comprising a compound having the formula




where n = 0 to about 8.

30 39. The composition of Claim 34 comprising a compound having the formula




and its pharmaceutically acceptable salt.

40. The composition of Claim 39 comprising a compound having the formula



and its pharmaceutically acceptable salt.


5 41. The composition of Claim 39 comprising a compound having the formula



15

20 and its pharmaceutically acceptable salt.

42. The composition of Claim 40 comprising a compound having the formula




30

and its pharmaceutically acceptable salt.

43. The composition of Claim 42 comprising a compound having the formula

10




20

and its pharmaceutically acceptable salt.

44. The composition of Claim 41 comprising a compound having the formula


30



and its pharmaceutically acceptable salt.


40 45. The composition of Claim 44 comprising a compound having the formula

50



and its pharmaceutically acceptable salt.


46. The composition of Claim 34 comprising a compound having the formula



5 and its pharmaceutically acceptable salt.

47. The composition of Claim 46 comprising a compound having the formula


15



and its pharmaceutically acceptable salt.

48. The composition of Claim 47 wherein R_3 has the formula

30



40


and its pharmaceutically acceptable salt.

49. The composition of Claim 48 comprising a compound having the formula

5

15

25




and its pharmaceutically acceptable salt.

50. The composition of Claim 48 having the formula

30


40



and its pharmaceutically acceptable salt.

51. The composition of Claim 47 having the formula

55




and its pharmaceutically acceptable salt.

5

52. The composition of Claim 51 comprising a compound having the formula


10



20

53. The composition of Claim 46 comprising a compound having the formula


30



40 and its pharmaceutically acceptable salt.

54. The composition of Claim 53 comprising a compound having the formula

45




55

and its pharmaceutically acceptable salt.

55. The composition of Claim 54 comprising a compound having the formula

10




20

and its pharmaceutically acceptable salt.

56. The composition of Claim 51 comprising a compound having the formula

30




40

and its pharmaceutically acceptable salt.

45

57. The composition of Claim 51 comprising a compound having the formula


50



and its pharmaceutically acceptable salt.

58. The composition of Claim 36 comprising a compound having the formula

10




and its pharmaceutically acceptable salt.

20

59. The composition of Claim 36 comprising a compound having the formula

30




40

and its pharmaceutically acceptable salt.

60. The composition of Claim 46 comprising a compound having the formula


50



and its pharmaceutically acceptable salt.

61. A method of treating inflammatory bowel disease or reducing inflammation which comprises administering to a patient an inflammation-reducing effective amount of a compound having the formula


15



- wherein R_2 is hydrogen, a monomeric glycoside or an oligomeric glycoside,
 R_3 is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula $\text{—CH(CH}_3\text{)C(=O)OCH}_2\text{O—R}_8$, R is a lower alkylene, R' is

- selected from the group consisting of moieties having the formula


25



where $X = 0$ or 1 , $Y = 0$ or 1 ,

- R_1 is hydrogen or a pharmacologically active drug residue, R_8 a pharmacologically active drug residue, R_4 , R_5 , and R_6 are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of

45



and R₇ is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, and the pharmaceutically acceptable salt thereof.

5 62. The method of Claim 61 wherein the patient is in need of therapy and the inflammatory bowel disease is Crohn's disease or ulcerative colitis.


63. The method of Claim 62 wherein the inflammatory bowel disease is Crohn's disease.

10


64. The method of 63 wherein the compound is administered orally.

65. A pharmaceutical composition useful for the treatment of inflammatory disease or for reducing inflammation which composition comprises an
15 inflammation reducing effective amount of a compound having the formula


25



30 wherein R₂ is hydrogen, a monomeric glycoside or an oligomeric glycoside, R₃ is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula




selected from the group consisting of moieties having the formula



35


where X = 0 or 1, Y = 0 or 1,

R₁ is hydrogen or a pharmacologically active drug residue, R₈ a pharmacologically active drug residue, R₄, R₅, and R₆ are independently
 5 hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




and R₇ is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, or a
 15 pharmaceutically acceptable salt thereof.

66. A pharmaceutical composition useful for the treatment of infectious disease or for reducing infection which composition comprises an infection reducing effective amount of a compound having the formula




wherein R₂ is hydrogen, a monomeric glycoside or an oligomeric glycoside, R₃ is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group
 35 having the formula $\text{—CH}(\text{CH}_3)\text{C}(=\text{O})\text{—OCH}_2\text{O—R}_8$, R is a lower alkylene, R' is

selected from the group consisting of moieties having the formula




where X = 0 or 1, Y = 0 or 1,

R₁ is hydrogen or a pharmacologically active drug residue, R₈ a
 5 pharmacologically active drug residue, R₄, R₅, and R₆ are independently
 hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing
 ring selected from the group consisting of




and R₇ is hydroxyl or hydroxyalkyl, with the proviso that said compound
 15 contains at least one pharmacologically active drug residue, or a
 pharmaceutically acceptable salt thereof.

67. A pharmaceutical composition useful for the treatment of glaucoma or for
 reducing intraocular pressure which composition comprises a therapeutically
 20 effective amount of a compound having the formula




35 wherein R₂ is hydrogen, a monomeric glycoside or an oligomeric glycoside,
 R₃ is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group
 having the formula $\text{—CH(CH}_3\text{)C(=O)—OCH}_2\text{O—R}_8$, R is a lower alkylene, R' is

selected from the group consisting of moieties having the formula



where X = 0 or 1, Y = 0 or 1,


R₁ is hydrogen or a pharmacologically active drug residue, R₈ a pharmacologically active drug residue, R₄, R₅, and R₆ are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing
 5 ring selected from the group consisting of



and R₇ is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

15


68.A pharmaceutical composition useful for administering therapeutic compositions ocularly for the treatment of systemic disorders, which composition comprises a therapeutically effective amount of a compound
 20 having the formula



30

wherein R₂ is hydrogen, a monomeric glycoside or an oligomeric glycoside, R₃ is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula $\text{—CH}(\text{CH}_3)\text{C}(=\text{O})\text{—OCH}_2\text{O—R}_8$, R is a lower alkylene, R' is
 35


selected from the group consisting of moieties having the formula



40


where X = 0 or 1, Y = 0 or 1,

R₁ is hydrogen or a pharmacologically active drug residue, R₈ a
pharmacologically active drug residue, R₄, R₅, and R₆ are independently
5 hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing
ring selected from the group consisting of



and R₇ is hydroxyl or hydroxyalkyl, with the proviso that said compound
contains at least one pharmacologically active drug residue, or a
15 pharmaceutically acceptable salt thereof.

69. A compound having the formula




20

wherein R₂ and R₃ are independently hydrogen, or a glycoside having the
formula

25


35



40

where n=0 to 8 and R₉ is an alkyl, alkylene, monocationic alkylamine or
polycationic alkylamine,


R is a lower alkylene, R' is



5


where X = 0 or 1, Y = 0 or 1, R₁ is hydrogen or a pharmacologically active drug residue, and R₄, R₅, and R₆ are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of

10




with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

20 70. The compound of Claim 69 wherein R₂ is hydrogen and R₃ is a glycoside having the formula



71. The compound of Claim 70 wherein R_3 is a glycoside having the formula



where $n=0$.


20

72. The compound of Claim 70 wherein R_9 is a monocationic alkylamine or polycationic alkylamine.

73. The compound of Claim 72 wherein the alkylamine is a quaternary amine.


25

74. The compound of Claim 71 having the formula



75. The compound of Claim 70 having the formula

5



20

76. The compound of Claim 75 wherein R_9 is a monocationic alkylamine or polycationic alkylamine.

77. The compound of Claim 76 wherein the alkylamine is a quaternary amine.

25